Guggenheim Lowers Illumina's Price Target to $150, Maintains 'Buy' Rating
Feb 08, 2025 15:27
CST Updated
15:27
Illumina
Diagnostic Product Developer
Gelonghui February 8 | Guggenheim: Downgrades Illumina's target price from $170 to $150, maintains "Buy" rating. (Gelonghui)